Stallergenes SA is a French biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, such as rhinoconjunctivitis, rhinitis and allergic asthma. It has developed a range of in vivo and in vitro tests for use in the medical profession. The Company's range of products includes more than 150 references. The Company also has research and development teams divided between clinical development, laboratory research and development of candidate products, and regulatory affairs. Stallergenes SA is present in almost 40 countries via ten subsidiaries in Europe in Germany, Italy, Spain, Belgium, Switzerland, the Netherlands, the Czech Republic, Slovakia, Austria and Great Britain, and has entered into numerous partnerships and distribution agreements. As of December 31, 2011, Stallergenes SA was 73.4%-owned by Ares Life Sciences.
